The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Clinical, Molecular, and Prognostic Significance of WHO Type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and Various Other 3q Abnormalities in Acute Myeloid Leukemia
Open accessAbstract
Purpose: Acute myeloid leukemia (AML) with inv(3)(q21q26.2)/t(3;3)(q21;q26.2) [inv(3)/t(3;3)] is recognized as a distinctive entity in the WHO classification. Risk assignment and clinical and genetic characterization of AML with chromosome 3q abnormalities other than inv(3)/t(3;3) remain largely unresolved. Patients and Methods: Cytogenetics, molecular genetics, therapy response, and outcome analysis were performed in 6,515 newly diagnosed adult AML patients. Patients were treated on Dutch-Belgian Hemato-Oncology Cooperative Group/Swiss Group for Clinical Cancer Research (HOVON/SAKK; n = 3,501) and German-Austrian Acute Myeloid Leukemia Study Group (AMLSG; n = 3,014) protocols. EVI1 and MDS1/EVI1 expression was determined by real-time quantitative polymerase chain reaction. Results: 3q abnormalities were detected in 4.4% of AML patients (288 of 6,515). Four distinct groups were defined: A: inv(3)/t(3;3), 32%; B: balanced t(3q26), 18%; C: balanced t(3q21), 7%; and D: other 3q abnormalities, 43%. Monosomy 7 was the most common additional aberration in groups (A), 66%; (B), 31%; and (D), 37%. N-RAS mutations and dissociate EVI1 versus MDS1/EVI1 overexpression were associated with inv(3)/t(3;3). Patients with inv(3)/t(3;3) and balanced t(3q21) at diagnosis presented with higher WBC and platelet counts. In multivariable analysis, only inv(3)/t(3;3), but not t(3q26) and t(3q21), predicted reduced relapse-free survival (hazard ratio [HR], 1.99; P < .001) and overall survival (HR, 1.4; P = .006). This adverse prognostic impact of inv(3)/t(3;3) was enhanced by additional monosomy 7. Group D 3q aberrant AML also had a poor outcome related to the coexistence of complex and/or monosomal karyotypes and cryptic inv(3)/t(3;3). Conclusion: Various categories of 3q abnormalities in AML can be distinguished according to their clinical, hematologic, and genetic features. AML with inv(3)/t(3;3) represents a distinctive subgroup with unfavorable prognosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933
Harrell, F. E. (2001) · Springer Series in Statistics · doi:10.1007/978-1-4757-3462-1 · Cited by 9,195
Proportional hazards tests and diagnostics based on weighted residuals
GRAMBSCH, P. M., & THERNEAU, T. M. (1994) · Biometrika · doi:10.1093/biomet/81.3.515 · Cited by 5,885
Döhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D., Larson, R. A., et al. (2010) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,373
Self-citationCheson, B. D., Bennett, J. M., Kopecky, K. J., Büchner, T., Willman, C. L., Estey, E. H., Schiffer, C. A., Doehner, H., Tallman, M. S., Lister, T. A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.036 · Cited by 2,654
Self-citationCreutzig, U., & Kaspers, G. J. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.99.116 · Cited by 2,137
Grimwade, D., Hills, R. K., Moorman, A. V., Walker, H., Chatters, S., Goldstone, A. H., Wheatley, K., Harrison, C. J., Burnett, A. K., & on behalf of the National Cancer Research Institute Adult Leukaemia Working Group (2010) · Blood · doi:10.1182/blood-2009-11-254441 · Cited by 1,938
Slovak, M. L., Kopecky, K. J., Cassileth, P. A., Harrington, D. H., Theil, K. S., Mohamed, A., Paietta, E., Willman, C. L., Head, D. R., Rowe, J. M., et al. (2000) · Blood · doi:10.1182/blood.v96.13.4075 · Cited by 1,601
Byrd, J. C. (2002) · Blood · doi:10.1182/blood-2002-03-0772 · Cited by 1,597
Estey, E., & Döhner, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69780-8 · Cited by 1,296
Self-citationCheson, B. D., Cassileth, P. A., Head, D. R., Schiffer, C. A., Bennett, J. M., Bloomfield, C. D., Brunning, R., Gale, R. P., Grever, M. R., & Keating, M. J. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.5.813 · Cited by 770
Breems, D. A., Van Putten, W. L. J., De Greef, G. E., Van Zelderen-Bhola, S. L., Gerssen-Schoorl, K. B. J., Mellink, C. H. M., Nieuwint, A., Jotterand, M., Hagemeijer, A., Beverloo, H. B., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.0259 · Cited by 580
Self-citationLöwenberg, B., van Putten, W., Theobald, M., Gmür, J., Verdonck, L., Sonneveld, P., Fey, M., Schouten, H., de Greef, G., Ferrant, A., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa025406 · Cited by 386
Self-citationBarjesteh van Waalwijk van Doorn-Khosrovani, S. (2003) · Blood · doi:10.1182/blood-2002-05-1459 · Cited by 355
Lugthart, S., van Drunen, E., van Norden, Y., van Hoven, A., Erpelinck, C. A. J., Valk, P. J. M., Beverloo, H. B., Löwenberg, B., & Delwel, R. (2008) · Blood · doi:10.1182/blood-2007-10-119230 · Cited by 280
Self-citationMorishita, K., Parganas, E., William, C. L., Whittaker, M. H., Drabkin, H., Oval, J., Taetle, R., Valentine, M. B., & Ihle, J. N. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.9.3937 · Cited by 276
Gröschel, S., Lugthart, S., Schlenk, R. F., Valk, P. J. M., Eiwen, K., Goudswaard, C., van Putten, W. J. L., Kayser, S., Verdonck, L. F., Lübbert, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.0646 · Cited by 256
Self-citationSchlenk, R. F., Dohner, K., Kneba, M., Gotze, K., Hartmann, F., del Valle, F., Kirchen, H., Koller, E., Fischer, J. T., Bullinger, L., et al. (2009) · Haematologica · doi:10.3324/haematol.13378 · Cited by 210
Self-citationFears, S., Mathieu, C., Zeleznik-Le, N., Huang, S., Rowley, J. D., & Nucifora, G. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.4.1642 · Cited by 197
Independent prognostic factors for AML outcome
Grimwade, D., & Hills, R. K. (2009) · Hematology · doi:10.1182/asheducation-2009.1.385 · Cited by 180
Censoring distributions as a measure of follow‐up in survival analysis
Korn, E. L. (1986) · Statistics in Medicine · doi:10.1002/sim.4780050306 · Cited by 166
Rubin, C., Larson, R., Anastasi, J., Winter, J., Thangavelu, M., Vardiman, J., Rowley, J., & Le Beau, M. (1990) · Blood · doi:10.1182/blood.v76.12.2594.2594 · Cited by 158
Suzukawa, K., Parganas, E., Gajjar, A. J., Abe, T., Takahashi, S., Tani, K., Asano, S., Asou, H., Kamada, N., & Yokota, J. (1994) · Blood · doi:10.1182/blood.v84.8.2681.2681 · Cited by 148
Löwenberg, B., Boogaerts, M. A., Daenen, S. M. G. J., Verhoef, G. E. G., Hagenbeek, A., Vellenga, E., Ossenkoppele, G. J., Huijgens, P. C., Verdonck, L. F., der Lelie, J. V., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.12.3496 · Cited by 126
Self-citationSchlenk, R. F., Benner, A., Hartmann, F., del Valle, F., Weber, C., Pralle, H., Fischer, J. T., Gunzer, U., Pezzutto, A., Weber, W. P., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2403009 · Cited by 119
Self-citationOssenkoppele, G. J. (2003) · Blood · doi:10.1182/blood-2003-07-2195 · Cited by 110
Breems, D. A., Boogaerts, M., Dekker, A. W., van Putten, W. L. J., Sonneveld, P., Huijgens, P. C., der Lelie, J. V., Vellenga, E., Gratwohl, A. A., Verhoef, G. E. G., et al. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05282.x · Cited by 73
Self-citationCharrin, C., Belhabri, A., Treille, D., Theuil, G. C., Magaud, J., Fiere, D. M., & Thomas, X. (2002) · The Hematology Journal · doi:10.1038/sj.thj.6200143 · Cited by 48
Grimwade, D. J., Hills, R. K., Moorman, A. V., Walker, H., Chatters, S., Goldstone, A. H., Wheatley, K., Harrison, C. J., & Burnett, A. K. (2010) · Research Portal (King's College London) · doi:10.25405/ncl.34131570 · Cited by 38
Lahortiga, I., Agirre, X., Belloni, E., Vázquez, I., Larráyoz, M. J., Gasparini, P., Lo‐Coco, F., Pelicci, P. G., Calasanz, M. J., & Odero, M. D. (2004) · Oncogene · doi:10.1038/sj.onc.1206923 · Cited by 33
Stevens‐Kroef, M., Poppe, B. G., van Zelderen‐Bhola, S., van den Berg, E., van der Blij‐Philipsen, M., van Kessel, A. G., Slater, R. M., Hamers, G., Michaux, L., Speleman, F., et al. (2004) · Leukemia · doi:10.1038/sj.leu.2403346 · Cited by 32
Diagnosis and Prognosis in Acute Myeloid Leukemia — The Art of Distinction
Löwenberg, B. (2008) · New England Journal of Medicine · doi:10.1056/nejme0802379 · Cited by 29
Self-citationvan Doorn-Khosrovani, S. B. V. W., Erpelinck-Verschueren, C. A. J., Löwenberg, B., & Delwel, R. (2003) · Experimental Hematology · doi:10.1016/j.exphem.2003.08.003 · Cited by 21
Self-citationVoutsadakis, I. A., & Maillard, N. (2003) · American Journal of Hematology · doi:10.1002/ajh.10248 · Cited by 17
Cited by
Döhner, H., Wei, A. H., Appelbaum, F. R., Craddock, C., DiNardo, C. D., Dombret, H., Ebert, B. L., Fenaux, P., Godley, L. A., Hasserjian, R. P., et al. (2022) · Blood · doi:10.1182/blood.2022016867 · Cited by 3,279
Self-citationTherapeutic Advances in Acute Myeloid Leukemia
Burnett, A., Wetzler, M., & Löwenberg, B. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.1820 · Cited by 787
Self-citationA Single Oncogenic Enhancer Rearrangement Causes Concomitant EVI1 and GATA2 Deregulation in Leukemia
Gröschel, S., Sanders, M. A., Hoogenboezem, R., de Wit, E., Bouwman, B. A. M., Erpelinck, C., van der Velden, V. H. J., Havermans, M., Avellino, R., van Lom, K., et al. (2014) · Cell · doi:10.1016/j.cell.2014.02.019 · Cited by 687
Self-citationAcute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management
Shimony, S., Stahl, M., & Stone, R. M. (2023) · American Journal of Hematology · doi:10.1002/ajh.26822 · Cited by 448
Recent advances in targeted therapies in acute myeloid leukemia
Bhansali, R. S., Pratz, K. W., & Lai, C. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01424-6 · Cited by 275
Metadata
- Authors
- Lugthart, S., Gröschel, S., Beverloo, H. B., Kayser, S., Valk, P. J. M., van Zelderen-Bhola, S. L., Jan Ossenkoppele, G., Vellenga, E., van den Berg-de Ruiter, E., Schanz, U., Verhoef, G., Vandenberghe, P., Ferrant, A., Köhne, C.-H., Pfreundschuh, M., Horst, H. A., Koller, E., von Lilienfeld-Toal, M., Bentz, M., Ganser, A., Schlegelberger, B., Jotterand, M., Krauter, J., Pabst, T., Theobald, M., Schlenk, R. F., Delwel, R., Döhner, K., Löwenberg, B., & Döhner, H.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-08-20
- Volume
- 28
- Issue
- 24
- Pages
- 3890-3898
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2170510628
- Cited by
- 256
- References
- 34
- FWCI
- 9.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.